Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma.

The goal of this clinical trial is to compare surgery plus reduced target chemoradiotherapy with surgery plus reduced dose chemoradiotherapy in newly diagnosed operable Nasopharyngeal Carcinoma.The main questions it aims to answer are:whether endoscopic surgery combined with reduced dose chemoradiotherapy vs surgery plus target reduction chemoradiotherapy can bring substantial survival benefits, lower toxicity, and shorter treatment cycle for patients with operable nasopharyngeal carcinoma .

NCT Number	NCT06529562
Lead Sponsor	Ming-Yuan Chen Collaborators: Fifth Affiliated Hospital, Sun Yat-Sen University, Sun Yat-sen University, Fifth Affiliated Hospital of Guangzhou Medical University, Huazhong University of Science and Technology Union Shenzhen Hospital, The First Affiliated Hospital of University of South China, People's Hospital of Guangxi Zhuang Autonomous Region, Nanchang City First Hospital
Conditions	Nasopharyngeal Carcinoma
Enrollment	384 participants
Start Date	2022-11-01
Primary Completion	2032-11-01 (estimated)
Study Completion	2032-11-01 (estimated)
Updated on ClinicalTrials.gov	2024-07-31